Tandem Diabetes coverage transferred with a Buy at TD Cowen

TD Cowen transferred coverage of Tandem Diabetes (TNDM) to analyst Mathew Blackman, who kept a Buy rating and raised the price target on the stock to $25. The firm called this a “differentiated call,” and sees key drivers of stock performance, adding that Tandem is a “a story stock,” but one it supports with “differentiated modeling and survey work.”